The Food and Drugs Authority (FDA) has revoked the Good Manufacturing Practices (GMP) certification of Aveo Pharmaceuticals, following a BBC Africa Eye investigation that exposed the company's alleged role in the illegal distribution of opioid-based medications across West Africa.
The investigation revealed that Aveo Pharmaceuticals, through Westfin International, exported unapproved drugs containing tapentadol and carisoprodol-powerful and highly addictive opioids-to Ghana, Nigeria, and Côte d'Ivoire.
These substances, when abused, pose severe health risks, including respiratory collapse and death.
In response, the FDA has directed Samos Pharma, a Ghanaian importer, to terminate all transactions with Aveo Pharmaceuticals and Westfin International.
